ATE452641T1 - Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate - Google Patents

Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate

Info

Publication number
ATE452641T1
ATE452641T1 AT03794351T AT03794351T ATE452641T1 AT E452641 T1 ATE452641 T1 AT E452641T1 AT 03794351 T AT03794351 T AT 03794351T AT 03794351 T AT03794351 T AT 03794351T AT E452641 T1 ATE452641 T1 AT E452641T1
Authority
AT
Austria
Prior art keywords
hydroxytestosterone
hydroxytestosterones
androsten
dihydroxy
derivatives
Prior art date
Application number
AT03794351T
Other languages
English (en)
Inventor
Evert Bunschoten
Bennink Herman Coelingh
Der Linden Rene Van
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of ATE452641T1 publication Critical patent/ATE452641T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03794351T 2002-09-05 2003-09-05 Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate ATE452641T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078643 2002-09-05
PCT/NL2003/000621 WO2004022065A1 (en) 2002-09-05 2003-09-05 Pharmaceutical application of 15- or 16- substituted testosterone analogues

Publications (1)

Publication Number Publication Date
ATE452641T1 true ATE452641T1 (de) 2010-01-15

Family

ID=31970390

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03794351T ATE452641T1 (de) 2002-09-05 2003-09-05 Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate

Country Status (9)

Country Link
US (1) US7943602B2 (de)
EP (1) EP1551415B1 (de)
CN (2) CN101785775B (de)
AT (1) ATE452641T1 (de)
AU (1) AU2003263663A1 (de)
CA (1) CA2497838C (de)
DE (1) DE60330695D1 (de)
ES (1) ES2338782T3 (de)
WO (1) WO2004022065A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE602005014227D1 (de) * 2004-03-10 2009-06-10 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
US7401307B2 (en) * 2004-11-03 2008-07-15 International Business Machines Corporation Slack sensitivity to parameter variation based timing analysis
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9352047B2 (en) * 2012-11-14 2016-05-31 Abon Pharmaceuticals, Llc Oral transmucosal drug delivery system
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
BR112017027688A2 (pt) 2015-06-22 2018-09-04 Lipocine Inc Composições orais que contêm éster de 17- hidroxiprogesterona e métodos relacionados
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (de) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. Pharmazeutische steroidhormonzusammensetzung
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793216A (en) * 1954-08-17 1957-05-21 Upjohn Co 15-oxy-androstenes and 15-oxy-19-norandrostenes
GB774064A (en) * 1954-08-17 1957-05-01 Upjohn Co Steroids
FR2035786A1 (en) * 1969-03-28 1970-12-24 Squibb & Sons Inc A-d-glucosides of steroids contng 16a-and 17-oh gps
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
EP1187618A1 (de) * 1999-06-04 2002-03-20 The General Hospital Corporation PHARMAZEUTISCHE FORMüLIERUNGEN ZUR BEHANDLUNG VON FRAUEN IN DER POSTMENOPAUSE UND PERIMENOPAUSE UND DEREN ANWENDUNG
CA2670236C (en) 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions

Also Published As

Publication number Publication date
CN1694710A (zh) 2005-11-09
CA2497838C (en) 2012-07-17
WO2004022065A1 (en) 2004-03-18
US7943602B2 (en) 2011-05-17
AU2003263663A1 (en) 2004-03-29
CA2497838A1 (en) 2004-03-18
EP1551415B1 (de) 2009-12-23
CN1694710B (zh) 2012-09-05
EP1551415A1 (de) 2005-07-13
ES2338782T3 (es) 2010-05-12
DE60330695D1 (de) 2010-02-04
CN101785775B (zh) 2015-03-25
US20060122158A1 (en) 2006-06-08
CN101785775A (zh) 2010-07-28

Similar Documents

Publication Publication Date Title
ATE452641T1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
JP6740497B2 (ja) 癌を治療するための方法及び組成物
Malini et al. Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates
US20080125401A1 (en) Use of estradiol valerate or 17beta-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido
ME00292B (me) Drospirenon za terapiju zamjene hormona
US20150290221A1 (en) Methods and compositions for treating cancer
SE463074B (sv) Anvaendning av aromatashaemmare och antiandrogener foer framstaellning av laekemedel foer profylax och terapi av benign prostatahyperplasi
CA2467222A1 (en) Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
HUP0102483A2 (hu) Androszt-5-én-3béta, 17béta-diolt tartalmazó gyógyszerkészítmények
CA2467237A1 (en) Method of preventing or treating benign gynaecological disorders
NZ312303A (en) Novel nor-pregnanes for inducing hypothalamic effects
WO2001003687A3 (en) Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans
NO955085L (no) Androstansteroider som nevrokjemiske initiatorer for forandring i menneskets hypotalamiske funksjon og beslektede farmasöytiske blandinger og metoder
MY128482A (en) New hormonal composition and its use
CA2258177A1 (en) 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
BR9307866A (pt) Esteróides estreno como iniciadores neuroquímicos de mudança em funçao hipotalamica humana e composiçoes farmaceuticas relacionadas e processos
RU2004116082A (ru) Применение (11бета, 17 бета)-11-(1,3-бензодиоксол-5-ил)-17-гидрокси-17-(1-пропинил) эстра-4,9-диен-3-она при лечении большого депрессивного расстройства
Nishino et al. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1, 4-diene-3, 17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
MX9700881A (es) Pregnanos y colanos como indicadores neuroquimicos del cambio en la funcion hipotalamica.
EE200300087A (et) 4-halogeenitud-17-metüleensteroidid, nende valmistamismeetod ja neid ühendeid sisaldavad farmatseutilised kompositsioonid
BR9816142A (pt) Esteróides de 19-nor-colano como iniciadores neuroquìmicos de mudança na função hipotalâmica humana
AR033260A1 (es) Nueva composicion hormonal y su utilizacion
JO2334B1 (en) Drospirenone for hormone replacement therapy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties